BR0208420A - Agente terapêutico para bexiga hiperativa, uso do composto tricìclico ou do sal farmaceuticamente aceitável do mesmo, e, método para o tratamento de bexiga hiperativa - Google Patents

Agente terapêutico para bexiga hiperativa, uso do composto tricìclico ou do sal farmaceuticamente aceitável do mesmo, e, método para o tratamento de bexiga hiperativa

Info

Publication number
BR0208420A
BR0208420A BR0208420-1A BR0208420A BR0208420A BR 0208420 A BR0208420 A BR 0208420A BR 0208420 A BR0208420 A BR 0208420A BR 0208420 A BR0208420 A BR 0208420A
Authority
BR
Brazil
Prior art keywords
overactive bladder
pharmaceutically acceptable
therapeutic agent
acceptable salt
bladder
Prior art date
Application number
BR0208420-1A
Other languages
English (en)
Inventor
Tsuyoshi Yamagata
Kaoru Atsuki
Tetsuji Ohno
Shiro Shirakura
Akira Karasawa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of BR0208420A publication Critical patent/BR0208420A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/12—[b,e]-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"AGENTE TERAPêUTICO PARA BEXIGA HIPERATIVA, USO DO COMPOSTO TRICìCLICO OU DO SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, E, MéTODO PARA O TRATAMENTO DE BEXIGA HIPERATIVA". Remédios para hiperatividade vesical que contém, como um ingrediente ativo, compostos tricíclicos representado pela fórmula geral (1) ou sais farmaceuticamente aceitáveis do mesmo: [onde R^ 1^ representa um átomo de hidrogênio, alquila inferior substituída ou não substituída, etc.; X^ 1^-X^ 2^-X^ 3^ representam CR^ 5^=CR^ 6^-CR^ 7^C=CR^ 8^, CR^ 5^=CR^ 6^-S, etc.; Y representa -CH~ 2~S-, -SOCH~ 2~-, etc.; e R^ 2^ representa hidrogênio, etc..
BR0208420-1A 2001-03-30 2002-03-29 Agente terapêutico para bexiga hiperativa, uso do composto tricìclico ou do sal farmaceuticamente aceitável do mesmo, e, método para o tratamento de bexiga hiperativa BR0208420A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001099801 2001-03-30
PCT/JP2002/003167 WO2002078710A1 (fr) 2001-03-30 2002-03-29 Medicaments contre l'hyperactivite vesicale

Publications (1)

Publication Number Publication Date
BR0208420A true BR0208420A (pt) 2004-03-30

Family

ID=18953304

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208420-1A BR0208420A (pt) 2001-03-30 2002-03-29 Agente terapêutico para bexiga hiperativa, uso do composto tricìclico ou do sal farmaceuticamente aceitável do mesmo, e, método para o tratamento de bexiga hiperativa

Country Status (12)

Country Link
US (1) US7276532B2 (pt)
EP (1) EP1384480A1 (pt)
JP (1) JPWO2002078710A1 (pt)
KR (1) KR20040007476A (pt)
CN (1) CN1498110A (pt)
BR (1) BR0208420A (pt)
CA (1) CA2442463A1 (pt)
EA (1) EA200301080A1 (pt)
HU (1) HUP0303608A3 (pt)
MX (1) MXPA03008725A (pt)
NO (1) NO20034356L (pt)
WO (1) WO2002078710A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004087131A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 鎮咳剤
AR044870A1 (es) * 2003-06-27 2005-10-05 Kyowa Hakko Kogyo Kk Compuesto azufrado triciclico y su uso como agente terapeutico para la vejiga hiperactiva
US20060160887A1 (en) * 2003-07-16 2006-07-20 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition
TW200522943A (en) * 2003-12-11 2005-07-16 Kyowa Hakko Kogyo Kk Fine crystallites and a pharmaceutical composition comprising them
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU700386B2 (en) 1995-10-16 1999-01-07 Kyowa Hakko Kogyo Co. Ltd. Triciclic compounds
JP3283267B2 (ja) 1997-04-15 2002-05-20 協和醗酵工業株式会社 三環式化合物

Also Published As

Publication number Publication date
HUP0303608A3 (en) 2007-06-28
KR20040007476A (ko) 2004-01-24
US20040116459A1 (en) 2004-06-17
MXPA03008725A (es) 2004-04-05
CA2442463A1 (en) 2002-10-10
EP1384480A1 (en) 2004-01-28
EA200301080A1 (ru) 2004-04-29
HUP0303608A2 (hu) 2004-03-01
NO20034356D0 (no) 2003-09-29
WO2002078710A1 (fr) 2002-10-10
JPWO2002078710A1 (ja) 2004-07-22
NO20034356L (no) 2003-11-27
US7276532B2 (en) 2007-10-02
CN1498110A (zh) 2004-05-19

Similar Documents

Publication Publication Date Title
BR0114436A (pt) Composto com anel de cinco elementos contendo nitrogênio alifático
EP1548008A4 (en) COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
CO5280078A1 (es) Compuestos
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
BR0014139A (pt) Derivado de diamida aromática ou um seu sal, composição agrìcola e hortìcola, e, método para utilizar uma composição agrìcola e hortìcola
BR9808552A (pt) Composto tricìclico ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
CO5031285A1 (es) Triarilimidazoles
BR0207025A (pt) Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo
ATE420639T1 (de) Antimykotische mittel
NO20045486L (no) Nye forbindelser og deres anvendelse
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
MX2009010559A (es) Derivados de heteroarilo.
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
BRPI0417345A (pt) compostos inibidores de quìnase baseados em azola, composições e seus usos
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0414780B8 (pt) composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto
EP1314719A4 (en) BENZOIC ACID DERIVATIVES AND MEDICAMENTS HAVING THE SAME AS ACTIVE INGREDIENT
AR035889A1 (es) Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos
BR0309558A (pt) Derivados de quinazolina e medicamentos
BR0208420A (pt) Agente terapêutico para bexiga hiperativa, uso do composto tricìclico ou do sal farmaceuticamente aceitável do mesmo, e, método para o tratamento de bexiga hiperativa
YU44202A (sh) Kvaternerne soli n-substituisanih cikiličnih ili ne- cikličnih amina kao farmaceutski preparati
BR0313566A (pt) Composto de 4-nitroimidazol 1-substituìdo, método para preparar um composto de 4-nitroimidazol, método para preparar um composto de 4-nitroimidazol 1-substituìdo, derivado de 4-nitroimidazol, e, composto
MX2023000693A (es) Inhibidor de egfr.
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
DE60216239D1 (de) Verwendung von cyclohexenon derivaten zur herstellung eines medikaments für die behandlung von dysurie

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.